论文部分内容阅读
血栓溶解疗法(纤溶疗法)是作为急性心肌梗塞、脑梗塞、肺梗塞、肾梗塞等的梗塞和四肢动脉闭塞等的治疗方法而发展起来的。一直沿用下来的纤溶酶激活剂的尿激酶(UK)和链激酶,因为对血栓无亲和性,为了使其效果确实而必须直接注入到流向血栓的动脉(负责动脉)中,并且,在全身给药时,必须大量用药,因为使全身的纤溶系统亢进,而有出血等很多副作用。另一方面,在机体血管内皮细胞等处产生的组织性纤溶酶激活剂(TPA)对纤维蛋白的亲和力很强,在血栓部位可发挥强大作用,在不太影响全身纤溶系统的情况下即可溶解血栓,因而引进开发了DNA重组技术,即重组TPA(recombigrant TPA)。
Thrombolytic therapy (fibrinolytic therapy) has been developed as a treatment for infarcts such as acute myocardial infarction, cerebral infarction, pulmonary infarction, renal infarction and the like and arterial occlusion of the extremities. Urokinase (UK) and streptokinase, which have been used as plasmin activators, have no affinity for thrombus and must be directly injected into the thrombogenic artery (in charge of an artery) in order to ensure their effect. In addition, Systemic administration, must be a lot of medication, because the body’s fibrinolytic system hyperthyroidism, while there are many side effects such as bleeding. On the other hand, tissue plasminogen activator (TPA), which is produced in body vascular endothelial cells and the like, has strong affinity for fibrin and exerts a strong effect on the thrombus site. When the systemic fibrinolytic system is not affected much Which can dissolve the thrombus, so the introduction of the development of recombinant DNA technology, recombinant TPA (recombigrant TPA).